Translumina
CompanyGermany
Translumina develops 2 assets, the furthest in human trials (Yukon Choice PC in coronaropathy). Mostly device acting on mTOR signalling and MTOR; based in Germany.
- 2
- Assets
- Furthest stage
- Human trials
- 1
- Trial
- 0
- Signals
Pipeline
2Sirolimus-eluting bioabsorbable polymer coronary stent system
Human trials, Device, mTOR signalling, MTOR, coronaropathy
Sirolimus-eluting bioabsorbable polymer coronary stent system
Human trials, Device, mTOR signalling, MTOR, coronaropathy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Similar companies3